Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

DNMT3A and NPM1 Double Mutated AML Is a Phenomenon of the Younger Patient and Could Represent a New Entity

Luca Vincenzo Cappelli, MD, Manja Meggendorfer, PhD, Frank Dicker, PhD, Sabine Jeromin, PhD, Stephan Hutter, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD, Alexander Höllein, MD

Blood (2018) 132 (Supplement 1): 2803.

https://doi.org/10.1182/blood-2018-99-113452

Published: 2018

Journal Articles

NPM1 Mutated AML Can Relapse with Wildtype NPM1 and Evolve with Novel Mutations: Implications for Pathobiology and MRD Monitoring

Alexander Höllein, MD, Manja Meggendorfer, PhD, Annette Fasan, PhD, Frank Dicker, PhD, Sabine Jeromin, PhD, Niroshan Nadarajah, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2017) 130 (Supplement 1): 1417.

https://doi.org/10.1182/blood.V130.Suppl_1.1417.1417

Published: 2017

Journal Articles

Characterization and Prognostic Impact of Multiple Productive IGHV Rearrangements in CLL

Sabine Jeromin, PhD, Claudia Haferlach, MD, Frank Dicker, PhD, Manja Meggendorfer, PhD, Torsten Haferlach, MD, Wolfgang Kern, MD

Blood (2016) 128 (22): 3207.

https://doi.org/10.1182/blood.V128.22.3207.3207

Published: 2016

Journal Articles

Patients with TP53 Disruption and IGHV Mutated Status Show Indolent Clinical Course: A Study on 1,327 Treatment-Naive CLL Cases

Sabine Jeromin, PhD, Claudia Haferlach, MD, Frank Dicker, PhD, Torsten Haferlach, MD, Wolfgang Kern, MD

Blood (2016) 128 (22): 4378.

https://doi.org/10.1182/blood.V128.22.4378.4378

Published: 2016

Journal Articles

Characterization of MYD88 mutated Lymphoplasmacytic Lymphoma in Comparison to MYD88 mutated Chronic Lymphocytic Leukemia

Constance Regina Baer, PhD, Frank Dicker, PhD, Wolfgang Kern, MD, Torsten Haferlach, Claudia Haferlach, MD

Blood (2015) 126 (23): 132.

https://doi.org/10.1182/blood.V126.23.132.132

Published: 2015

Journal Articles

WT1 Mutations Are Secondary Events In AML and Show Varying Frequencies Within Genetic Subgroups and Different Impact On Prognosis

Susanne Schnittger, PhD, Christiane Eder, PhD, Tamara Alpermann, Frank Dicker, PhD, Madlen Ulke, Alexander Kohlmann, PhD, Sabrina Kuznia, MSc, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2013) 122 (21): 2542.

https://doi.org/10.1182/blood.V122.21.2542.2542

Published: 2013

Journal Articles

Comparison Of Mutation Patterns Between Diagnosis and Relapse In 556 Adult Patients With AML Shows High Variability Of Stability

Susanne Schnittger, PhD, Niroshan Nadarajah, MSc, Tamara Alpermann, Christiane Eder, PhD, Alexander Kohlmann, PhD, Sabrina Kuznia, MSc, Sandra Weissmann, PhD, Annette Fasan, PhD, Simone Weber, Andreia Albuquerque, PhD, Sabine Jeromin, PhD, Manja Meggendorfer, PhD, Frank Dicker, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2013) 122 (21): 4978.

https://doi.org/10.1182/blood.V122.21.4978.4978

Published: 2013

Journal Articles

IGHV Mutation Status Does Not Add Prognostic Information In The Background Of Mutations In TP53 and SF3B1, and Deletions Of 17p and 11q, Which Are Independent Adverse Prognostic Parameters In CLL

Claudia Haferlach, MD, Sabine Jeromin, PhD, Sandra Weissmann, PhD, Frank Dicker, PhD, Wolfgang Kern, MD, Susanne Schnittger, PhD, Alexander Kohlmann, PhD, Torsten Haferlach, MD

Blood (2013) 122 (21): 4110.

https://doi.org/10.1182/blood.V122.21.4110.4110

Published: 2013

Journal Articles

Risk Stratification In Chronic Lymphocytic Leukemia Patients With IGHV3-21 Gene Usage According To Presence Of Stereotypy and Mutations In SF3B1

Sabine Jeromin, PhD, Frank Dicker, PhD, Katharina Bayer, Sandra Weissmann, PhD, Christiane Eder, PhD, Manja Meggendorfer, PhD, Tamara Alpermann, Alexander Kohlmann, PhD, Torsten Haferlach, MD, Wolfgang Kern, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD

Blood (2013) 122 (21): 4114.

https://doi.org/10.1182/blood.V122.21.4114.4114

Published: 2013

Journal Articles

Characterization and Quantification Of Rare BCR-ABL1 Fusion Transcripts

Susanne Schnittger, PhD, Frank Dicker, PhD, Tamara Alpermann, Christiane Eder, PhD, Annette Fasan, PhD, Simone Weber, Sabine Jeromin, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2013) 122 (21): 4013.

https://doi.org/10.1182/blood.V122.21.4013.4013

Published: 2013

Journal Articles

Evaluation Of Different NPM1 Mutations In AML Patients According To Clinical, Cytogenetic and Molecular Features and Impact On Outcome

Tamara Alpermann, Claudia Haferlach, MD, Frank Dicker, PhD, Christiane Eder, PhD, Alexander Kohlmann, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Susanne Schnittger, PhD

Blood (2013) 122 (21): 51.

https://doi.org/10.1182/blood.V122.21.51.51

Published: 2013

Journal Articles

Tyrosine Kinase Inhibitor Treated CML Patients Harboring Philadelphia-Negative Cytogenetically Aberrant Clones Show Molecular Mutations In 31% Of Cases Not Present At Diagnosis: A High-Throughput Amplicon Sequencing Study Of 29 Genes

Susanne Schnittger, PhD, Sabrina Kuznia, MSc, Manja Meggendorfer, PhD, Niroshan Nadarajah, MSc, Sabine Jeromin, PhD, Tamara Alpermann, Andreas Roller, PhD, Andreia Albuquerque, PhD, Sandra Weissmann, PhD, Thomas Ernst, Christiane Eder, PhD, Frank Dicker, PhD, Wolfgang Kern, MD, Alexander Kohlmann, PhD, Torsten Haferlach, MD, Andreas Hochhaus, MD, Claudia Haferlach, MD

Blood (2013) 122 (21): 611.

https://doi.org/10.1182/blood.V122.21.611.611

Published: 2013

Journal Articles

TP53 Alterations In CLL - Parameters Influencing The Prognostic Impact: A Study On 3,988 Patients

Claudia Haferlach, MD, Frank Dicker, PhD, Sabine Jeromin, PhD, Sandra Weissmann, PhD, Andreas Roller, PhD, Wenke Worseg, Tamara Alpermann, Wolfgang Kern, MD, Torsten Haferlach, MD, Alexander Kohlmann, PhD, Susanne Schnittger, PhD

Blood (2013) 122 (21): 865.

https://doi.org/10.1182/blood.V122.21.865.865

Published: 2013

Journal Articles

High BAALC Expression in Cytogenetically Normal Acute Myeloid Leukemia Strongly Correlates with Adverse Markers Such As RUNX1 mut, MLL -PTD and FLT3 -ITD and Is Useful for Disease Monitoring

Simone Weber, Tamara Alpermann, Christiane Eder, PhD, Frank Dicker, PhD, Sabine Jeromin, PhD, Alexander Kohlmann, PhD, Annette Fasan, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD, Susanne Schnittger, PhD

Blood (2012) 120 (21): 1376.

https://doi.org/10.1182/blood.V120.21.1376.1376

Published: 2012

Journal Articles

Acquisition of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients During the Course of Disease Is Associated with an Unmutated IGHV Status and Mutations in XPO1 and SF3B1

Vera Grossmann, MSc, Alexander Kohlmann, PhD, Susanne Schnittger, PhD, Sandra Weissmann, PhD, Frank Dicker, PhD, Sabine Jeromin, PhD, Lucia Boeck, Tamara Alpermann, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2012) 120 (21): 1768.

https://doi.org/10.1182/blood.V120.21.1768.1768

Published: 2012

Journal Articles

Evaluation of BRAF V600E, NRAS and KRAS Mutations As Well As IGHV Usage for Diagnostic Use in Hairy Cell Leukemia, Hairy Cell Leukemia-Variant and Splenic Marginal Zone Lymphoma.

Susanne Schnittger, PhD, Frank Dicker, PhD, Christiane Eder, PhD, Sabine Jeromin, PhD, Tamara Alpermann, Claudia Haferlach, MD, Torsten Haferlach, MD, Wolfgang Kern, MD

Blood (2012) 120 (21): 2679.

https://doi.org/10.1182/blood.V120.21.2679.2679

Published: 2012

Journal Articles

CML Patients with Philadelphia-Negative Clones Occurring During Treatment with Tyrosine Kinase Inhibitors Harbor Molecular Mutations Typical for MDS.

Susanne Schnittger, PhD, Christiane Eder, PhD, Alexander Kohlmann, PhD, Frank Dicker, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2012) 120 (21): 2775.

https://doi.org/10.1182/blood.V120.21.2775.2775

Published: 2012

Journal Articles

SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients

Sabine Jeromin, PhD, Claudia Haferlach, MD, Katharina Bayer, Frank Dicker, PhD, Sandra Weissmann, PhD, Vera Grossmann, MSc, Tamara Alpermann, Alexander Kohlmann, PhD, Torsten Haferlach, MD, Wolfgang Kern, MD, Susanne Schnittger, PhD

Blood (2012) 120 (21): 709.

https://doi.org/10.1182/blood.V120.21.709.709

Published: 2012

Journal Articles

The Impact of Homozygosity and Size of the 13q Deletion in Patients with CLL

Claudia Haferlach, MD, Melanie Zenger, Vera Grossmann, MSc, Frank Dicker, PhD, Sabine Jeromin, PhD, Alexander Kohlmann, PhD, Susanne Schnittger, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2012) 120 (21): 3892.

https://doi.org/10.1182/blood.V120.21.3892.3892

Published: 2012

Journal Articles

SF3B1 Mutations Are Detectable in 48.9% of Acute Myeloid Leukemia with Normal Karyotype (AML-NK) and ≥15% Ring Sideroblasts and Are Closely Related to FLT3 -ITD and RUNX1 Mutations

Sabine Jeromin, PhD, Ulrike Bacher, MD, Katharina Bayer, Frank Dicker, PhD, Christiane Eder, PhD, Annette Fasan, PhD, Vera Grossmann, MSc, Alexander Kohlmann, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD

Blood (2012) 120 (21): 406.

https://doi.org/10.1182/blood.V120.21.406.406

Published: 2012

NARROW

DNMT3A and NPM1 Double Mutated AML Is a Phenomenon of the Younger Patient and Could Represent a New Entity

NPM1 Mutated AML Can Relapse with Wildtype NPM1 and Evolve with Novel Mutations: Implications for Pathobiology and MRD Monitoring

Characterization and Prognostic Impact of Multiple Productive IGHV Rearrangements in CLL

Patients with TP53 Disruption and IGHV Mutated Status Show Indolent Clinical Course: A Study on 1,327 Treatment-Naive CLL Cases

Characterization of MYD88 mutated Lymphoplasmacytic Lymphoma in Comparison to MYD88 mutated Chronic Lymphocytic Leukemia

WT1 Mutations Are Secondary Events In AML and Show Varying Frequencies Within Genetic Subgroups and Different Impact On Prognosis

Comparison Of Mutation Patterns Between Diagnosis and Relapse In 556 Adult Patients With AML Shows High Variability Of Stability

IGHV Mutation Status Does Not Add Prognostic Information In The Background Of Mutations In TP53 and SF3B1, and Deletions Of 17p and 11q, Which Are Independent Adverse Prognostic Parameters In CLL

Risk Stratification In Chronic Lymphocytic Leukemia Patients With IGHV3-21 Gene Usage According To Presence Of Stereotypy and Mutations In SF3B1

Characterization and Quantification Of Rare BCR-ABL1 Fusion Transcripts

Evaluation Of Different NPM1 Mutations In AML Patients According To Clinical, Cytogenetic and Molecular Features and Impact On Outcome

Tyrosine Kinase Inhibitor Treated CML Patients Harboring Philadelphia-Negative Cytogenetically Aberrant Clones Show Molecular Mutations In 31% Of Cases Not Present At Diagnosis: A High-Throughput Amplicon Sequencing Study Of 29 Genes

TP53 Alterations In CLL - Parameters Influencing The Prognostic Impact: A Study On 3,988 Patients

High BAALC Expression in Cytogenetically Normal Acute Myeloid Leukemia Strongly Correlates with Adverse Markers Such As RUNX1 mut, MLL -PTD and FLT3 -ITD and Is Useful for Disease Monitoring

Acquisition of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients During the Course of Disease Is Associated with an Unmutated IGHV Status and Mutations in XPO1 and SF3B1

Evaluation of BRAF V600E, NRAS and KRAS Mutations As Well As IGHV Usage for Diagnostic Use in Hairy Cell Leukemia, Hairy Cell Leukemia-Variant and Splenic Marginal Zone Lymphoma.

CML Patients with Philadelphia-Negative Clones Occurring During Treatment with Tyrosine Kinase Inhibitors Harbor Molecular Mutations Typical for MDS.

SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients

The Impact of Homozygosity and Size of the 13q Deletion in Patients with CLL

SF3B1 Mutations Are Detectable in 48.9% of Acute Myeloid Leukemia with Normal Karyotype (AML-NK) and ≥15% Ring Sideroblasts and Are Closely Related to FLT3 -ITD and RUNX1 Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only